Atrial fibrillation (AFib) was confirmed in nearly 94% of people who were initially identified to have signs of the heart rhythm disorder by a smartwatch application and who followed up with a clinician, in a study presented at the American College of Cardiology’s 71st Annual Scientific Session.
The study, which involved more than 2.8 million participants, is the largest study to date to demonstrate how wearable consumer technologies can be used to screen for heart problems during everyday activities. Researchers also used the app to screen a subset of participants for obstructive sleep apnea and found that people flagged for possible sleep apnea were 1.5 times more likely to have AFib than those who were not. This suggests that tools suitable for detecting the two conditions can work synergistically to further enhance health monitoring.
“Digital technologies make it possible to increase general awareness about AFib and its risk factors as well as to improve prevention of AFib and its complications,” said Yutao Guo, MD, professor of internal medicine at Chinese PLA Medical School and Chinese PLA General Hospital in Beijing and the study’s lead author. “With the global surge of wearable technology for AFib screening, especially in the challenging setting of the COVID-19 pandemic, the present study provides a possible solution to help people identify possible signs of AFib and get diagnosed and treated earlier.”
AFib is the most common type of heart rhythm disorder, with symptoms including a rapid or irregular heartbeat along with episodes of lightheadedness, chest pain and shortness of breath. People with AFib are about five times more likely to suffer a stroke compared with the general population because an erratic heartbeat can cause blood to pool and clot. However, this risk can be lowered with early diagnosis and treatment.
The study, conducted in China, combined data from smart devices with clinical data to examine the accuracy of AFib screening using photoplethysmography, a light-based method to monitor blood flow used in many wearable devices. Researchers tracked more than 2.8 million people who downloaded an AFib screening app on a compatible Huawei smart device (a consumer electronics brand popular in China). The smart device uses photoplethysmography to monitor the wearer’s pulse and the app applies an algorithm to detect when the heart rhythm is abnormal. If an abnormal rhythm was detected, the wearer would be contacted by a clinician to set up an appointment for a clinical assessment.
Over the course of four years (2018-2021), 12,244 users received a notification of suspected AFib. Among 5,227 people who chose to follow up with a clinician, AFib was confirmed in 93.8% of patients using standard AFib diagnostic tools including clinical evaluation, an electrocardiogram and 24-hour Holter monitoring, where someone wears a device to track heart activity while they go about their usual activities including sleeping.
Photoplethysmography can also be used to detect physiological changes that occur when a person has obstructive sleep apnea, a condition that disrupts breathing during sleep. Previous studies have suggested that about half of people with AFib also have sleep apnea. In this study, 961,931 of the app users screened for AFib were also screened for signs of sleep apnea. Of these, about 18,000 were notified they may have the condition. Results also showed a high rate of AFib diagnosis among this group, with 1.5-fold higher odds of receiving an AFib diagnosis among those who were flagged for sleep apnea compared to those who were not.
“This consumer-led AFib screening approach highlights the increased risk for detecting prevalent AFib episodes over time and the need for modification of obstructive sleep apnea and other risk factors that increase AFib susceptibility,” Guo said. “Future studies will be needed to move toward using ‘smart’ technology to help manage AFib and the risk factors that increase AFib susceptibility, as well as to evaluate attitudes and concerns related to this digital health tool.”
While the study used Huawei devices, more common devices in the U.S. such as the Apple Watch or FitBit have similar photoplethysmography technology that can be used to measure a person’s pulse and detect abnormalities.
One limitation of the study is that only 53.3% of those who received a notification of suspected AFib effectively followed up with a clinician for further evaluation. Researchers were unable to verify whether the remaining individuals had clinically confirmed AFib or determine why they did not follow up for a health assessment.
The study was funded by the National Natural Science Foundation of China.
Guo will present the study, “Consumer-led Screening for Atrial Fibrillation: A Report from the mAFA-II Trial Long-term Extension Cohort,” on Sunday, April 3, at 12:15 p.m. ET / 16:15 UTC in the Main Tent, Hall D.
ACC.22 will take place April 2-4, 2022, in Washington, DC, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC22 for the latest news from the meeting.
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit ACC.org.